ArticleNano letters2020
Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs.
Abstract read
In one paragraph
Article in Nano letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Injectables Protein-Based Nanodiscs in Cancer Drug Delivery: From Bench to Clinical Potential.AAPS PharmSciTech · 2025Review
- Emerging nanoparticles that target and eliminate cancer stem cells.Nanomedicine (London, England) · 2025Review
- Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.International journal of biological sciences · 2025Review
- Novel strategies for nanovaccine application in breast cancer treatment.Frontiers in pharmacology · 2025Review
- Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma.International journal of molecular sciences · 2024Article
- Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioactive materials · 2024Review
- Targeting lymph nodes for enhanced cancer vaccination: From nanotechnology to tissue engineering.Materials today. Bio · 2024Review
- Nanobiotechnology augmented cancer stem cell guided management of cancer: liquid-biopsy, imaging, and treatment.Journal of nanobiotechnology · 2024Review
- Multi-Omics profiling identifies aldehyde dehydrogenase 2 as a critical mediator in the crosstalk between Treg-mediated immunosuppression microenvironment and hepatocellular carcinoma.International journal of biological sciences · 2024Article
- Cancer Stem Cells in Colorectal Cancer: Implications for Targeted Immunotherapies.Journal of gastrointestinal cancer · 2023Review
- Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.Journal of translational medicine · 2023Review
- Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.Journal of nanobiotechnology · 2023Review
- Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.Advanced healthcare materials · 2023Article
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Eradicating the tumor "seeds": nanomedicines-based therapies against cancer stem cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023Review
- Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.Journal of nanobiotechnology · 2023Article
- Immunotargeting of Cancer Stem Cells.Cancers · 2023Review
- Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets.MedComm · 2023Review
- Review
- Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Alireza Hassani NajafabadiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jing ZhangDepartment of Surgery, University of Michigan, Ann Arbor, Michigan 48109, United States.
Marisa E AikinsDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Zeynab Izadi Najaf AbadiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Fei LiaoDepartment of Surgery, University of Michigan, Ann Arbor, Michigan 48109, United States.
You QinDepartment of Surgery, University of Michigan, Ann Arbor, Michigan 48109, United States.
Emeka B OkekeDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Lindsay M ScheetzDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jutaek NamDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Yao XuDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
David AdamsBiomedical Research Core Facilities, University of Michigan, Ann Arbor, Michigan 48109, United States.
Patrick LesterUnit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Taryn HetrickUnit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Anna SchwendemanDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-8023-8080
Max S WichaDepartment of Surgery, University of Michigan, Ann Arbor, Michigan 48109, United States.
Alfred E ChangDepartment of Surgery, University of Michigan, Ann Arbor, Michigan 48109, United States.
Qiao LiDepartment of Surgery, University of Michigan, Ann Arbor, Michigan 48109, United States.
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0003-2238-2372
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2MUniversity of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OMARY, BISHR · 1986 to 2021
$22.5MTargeting breast cancer stem cellsR35CA197585 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WICHA, MAX S. · 2016 to 2022
$6.4MKLF14 and Cardiovascular DiseaseR01HL134569 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHEN, YUQING EUGENE · 2017 to 2024
$5.3MNovel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5MElicitation of mucosal immune responses against HIVR01AI127070 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2020
$2.3MNanomaterials for eliciting anti-tumor T-cells-Diversity SupplementR01CA210273 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2017 to 2021
$2.2MTuning Biomaterials-immune cell interactions for treatment of glioblastoma multiformeR01EB022563 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2019
$1.7MOptimization of synthetic HDL nanoparticles for treatment Niemann-Pick Type CR21NS111191 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHWENDEMAN, ANNA · 2019 to 2019
$429kHDL-Loaded Nanoparticles for Glioma TherapeuticsR21NS091555 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2016
$427kCIHRNCI NIH HHS P30 CA046592NCI NIH HHS R01 CA210273NCI NIH HHS R35 CA197585NHLBI NIH HHS R01 HL134569NIAID NIH HHS R01 AI127070NIBIB NIH HHS R01 EB022563NIDDK NIH HHS P30 DK034933NIDDK NIH HHS R01 DK125087NINDS NIH HHS R21 NS091555NINDS NIH HHS R21 NS111191
Abstract
Cancer stem cells (CSCs) proliferate extensively and drive tumor metastasis and recurrence. CSCs have been identified in over 20 cancer types to date, but it remains unknown how to target and eliminate CSCs in vivo. Aldehyde dehydrogenase (ALDH) is a marker that has been used extensively for isolating CSCs. Here we present a novel approach to target and reduce the frequency of ALDH
Indexed as
NeoplasmsVaccinesAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyAnimalsCell Line, TumorImmunotherapyMiceNeoplastic Stem CellsAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyVaccinesaldehyde dehydrogenasebreast cancerCancer stem cellscancer vaccinemelanoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.